Prof. Dr. med. Fabian Müller

Department of Medicine 5 – Haematology and Oncology Professur für CAR-T-Zell-Therapie

Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment (2025) Pelzl R, Benintende G, Gsottberger F, Scholz JK, Rübner M, Yao H, Wendland K, et al. Journal article Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma (2025) Shumilov E, Scholz JK, Seib M, Mazzeo P, Wurm-Kuczera R, Vucinic V, Holtick U, et al. Journal article One CHiP to rule them all? Mechanistic insight into carfilzomib-induced lung injury with neutrophil extracellular trap formation following cellular immunotherapy (2025) Scholz JK, Stabel L, Schwingen NR, Knopf J, Flatt AS, Bäuerle T, Krause S, et al. Journal article, Medical case study BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells (2025) Müller F, Wirsching A, Hagen M, Völkl S, Tur C, Raimondo MG, Taubmann J, et al. Journal article Langzeitverlauf von Effizienz und Sicherheit der CD19-CAR T-Zell-Therapie beim systemischen Lupus erythematodes (2025) Taubmann J, Böltz S, Hagen M, Wirsching A, Müller F, Völkl S, Kharboutli S, et al. Journal article Effects of different B-cell-depleting strategies on the lymphatic tissue (2025) Tur C, Eckstein M, Bucci L, Auth J, Bergmann C, Rauber S, Hagen M, et al. Journal article Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma (2025) Müller F, Schwingen NR, Hagen M, Scholz JK, Aigner M, Wirsching A, Taubmann J, et al. Journal article CAR-T-Zellen bei nicht-malignen Erkrankungen (2025) Müller F, Hagen M, Schett G, Mackensen A Journal article Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study (2025) Hagen M, Müller F, Wirsching A, Kharboutli S, Spörl S, Düsing C, Krickau T, et al. Journal article Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study (2025) Merz M, Albici AM, von Tresckow B, Rathje K, Fenk R, Holderried T, Müller F, et al. Journal article